RAFAEL HOLDINGS INC-CLASS B (RFL)
US75062E1064 - Common Stock
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments ...
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
Rafael Holdings just reported results for the first quarter of 2024.
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rafael Holdings (NYSE:RFL) just reported results for the first quarter of 2024....
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments...
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities...
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase...
Cyclo Therapeutics and Rafael enter agreement for $5M funding (NASDAQ:CYTH)
Clinical stage biotechnology company, Cyclo Therapeutics (CYTH) enters into an agreement with Rafael (RFL) to purchase 4M shares and warrants for an aggregate purchase price of $5M
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers that investors need to know about on Wednesday morning!
(NYSE:RFL)
Rafael Holdings (RFL) has announced that its Board of Directors has authorized the repurchase of up to $5M of the Co.'s Class B common stock. the current macroeconomic environment,...
Rafael Holdings Announces up to $5 Million Share Repurchase Program
Announces expanded search for strategic opportunities beyond biopharma
Rafael Holdings Announces up to $5 Million Share Repurchase Program
Announces expanded search for strategic opportunities beyond biopharma...
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results
NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for...
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its first quarter fiscal 2023 financial results for the...
Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced its decision to curtail its early-stage development...
Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
NEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), a holding company with interests in clinical and early-stage...
Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer
Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in...
Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage
NEWARK, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), an early-stage novel cancer and immune metabolism therapeutics...
Friday 7/8 Insider Buying Report: RFL, BRK.A
Top Buys by Directors: Jonas's $6M Bet on RFL
Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
CRANBURY, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...
Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer...